By Sheeba M. | April 18, 2026
Curaleaf’s International Push: Can a US-Centric MSO Win in European Cannabis Markets?
Curaleaf Holdings (CSE: CURLF, OTC: CURLF) has spent the last three years building what is arguably the most internationally diversified asset base of any major US cannabis company. Through acquisitions in the UK, Germany, Italy, and Portugal, Curaleaf has positioned itself ahead of what many analysts expect to be a wave of European medical cannabis market liberalization.
Why Europe Is Different
Unlike the US state-by-state patchwork, European cannabis markets are largely prescription-based medical systems with national regulatory frameworks. That means a completely different go-to-market approach — no retail dispensaries, heavy reliance on pharmaceutical distribution channels, and pricing that is often negotiated at the national level or through tender processes.
Curaleaf’s European assets include European subsidiaries that hold cultivation and distribution licenses in multiple jurisdictions. The German market, in particular, has been in focus: Germany legalized medical cannabis in 2017 and has been steadily expanding patient access, with recreational reform passing in 2024. That makes it the largest potential cannabis market in Europe.
US Operations Still Fuel the Business
For all the international diversification, CURLF remains fundamentally a US-focused operator. The company’s 2025 revenue mix was roughly 85% domestic, with the international segment growing but still loss-making at the operating level. That’s a meaningful consideration for investors: the European upside is real, but it comes with a near-term cost drag.
On the domestic side, Curaleaf competes directly with VRNO (Verano Holdings) and AAWH (Ascend Wellness) in core markets like New Jersey, Illinois, and Florida. Curaleaf’s scale gives it pricing power and brand reach that smaller regional players can’t match, but it also carries higher overhead and more complex regulatory exposure across dozens of states.
The Regulatory Wild Card
European regulatory frameworks are tightening rather than loosening in the near term. Germany’s recreational legalization was a landmark, but implementation timelines are slow and pharmaceutical grade requirements add complexity that recreational-first operators aren’t used to. Companies like Aurora Cannabis and Tilray — with established European operations — have a structural head start in those channels.
The key question for CURLF investors: Can the company run its European operations efficiently enough to break even before US cash flow gets squeezed by continued state-level pricing pressure?
Sources
- Curaleaf Investor Relations — Annual reports and regulatory filings
- Reuters — European cannabis market regulatory updates
Track cannabis stocks with the Weedstock Real-Time Tracker